The content on this site is intended for healthcare professionals only
During a press confernece at SABCS 2013, Dr Sherene Loi presents data on women with HER2-positive breast cancer who had the highest levels of immune cells in their tumours and how they gained the most benefit from presurgery treatment with chemotherapy and trastuzumab.
“Our new data further support the positive relationship between tumour-infiltrating lymphocytes and better outcomes with trastuzumab therapy, this time in a cohort of patients with newly diagnosed HER2-positive breast cancer who received the therapy before surgery.
“It seems, therefore, that levels of tumour-infiltrating lymphocytes may be a good biomarker of response to trastuzumab in primary breast cancer, something that researchers have been looking for with little success for some time,” added Loi.
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status
OncoAlert round up July 28th to August 3rd, 2023
Updates on triple-negative breast cancer and immunotherapy
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Management of HER2 positive metastatic breast cancer treatment algorithm
Post neoadjuvant management in BRCA mutant breast cancer patients
